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1. INTRODUCTION {#cam42358-sec-0001}
===============

Thin melanomas measuring 1 mm or less account for approximately 50% of all melanomas diagnosed in our area.[1](#cam42358-bib-0001){ref-type="ref"} Although thin melanomas have a good prognosis, the absolute number of deaths is very high due to the sheer number of cases.[2](#cam42358-bib-0002){ref-type="ref"}

Before the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual,[3](#cam42358-bib-0003){ref-type="ref"} most clinical guidelines recommended sentinel lymph node biopsy (SLNB) for patients with thin melanoma and additional risk factors, such as tumor thickness ≥0.75 mm, ulceration, mitosis, and a high Clark level.[4](#cam42358-bib-0004){ref-type="ref"} The decision to perform SLNB in patients with melanoma ≤1 mm should be made by weighing the likelihood of detecting SLN metastasis, established as an expected rate of at least 5%,[5](#cam42358-bib-0005){ref-type="ref"} against the potential complications, not to mention cost, of the procedure.[6](#cam42358-bib-0006){ref-type="ref"} A recent systematic review and meta‐analysis established that the presence of at least one mitosis was the most important predictor of SLN metastasis with respect to adjusted variables in patients with thin melanoma.[7](#cam42358-bib-0007){ref-type="ref"} However, in the new edition of the AJCC Cancer Staging Manual,[3](#cam42358-bib-0003){ref-type="ref"} mitotic rate is no longer considered a staging criterion for thin melanoma, although its prognostic value is still clearly recognized. The only two updated clinical practice guidelines---version 1.2018 of the National Comprehensive Cancer Network (NCCN) guidelines (version 1.2018)[8](#cam42358-bib-0008){ref-type="ref"} and the American Society of Clinical Oncology‐Society of Surgical Oncology (ASCO‐SSO) guideline[9](#cam42358-bib-0009){ref-type="ref"}---recommend discussing and considering SLNB in patients with T1b melanoma (ulcerated tumors or tumors with a Breslow thickness ≥0.8 mm). The NCCN guidelines additionally recommend considering SLNB in patients with T1a melanoma (tumors \<0.8 mm without ulceration) when ≥2 mitoses/mm^2^ are observed, especially in young patients or patients with lymphovascular invasion.

The main objective of this study was to identify prognostic factors for thin melanoma and predictive factors associated with SLN involvement in a large multicenter cohort of patients with melanoma.

2. MATERIALS AND METHODS {#cam42358-sec-0002}
========================

We designed a multicenter observational study based on the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.[10](#cam42358-bib-0010){ref-type="ref"} Patients were recruited in nine hospitals that formed part of the Sentinel Lymph Node Study Group in Melanoma (SENTIMEL). Patients with melanoma were selected from the databases of seven Spanish hospitals (Instituto Valenciano de Oncología \[IVO\] in Valencia, Hospital Universitario de Salamanca \[HUS\] in Salamanca, Hospital La Fe \[HLF\] in Valencia, Hospital Virgen Macarena \[HVM\] in Seville, Hospital de la Coruña \[HC\] in A Coruña, Hospital German Trials i Pujol \[HGT\] in Badalona, and Hospital Clìnic \[HC\] in Barcelona) and two hospitals outside Spain (Hopital de Coimbra \[HCo\] in Portugal and Hospital de Turin \[HT\] in Italy). All the hospitals are tertiary care hospitals and reference centers for melanoma. Patients registered in any of the databases up to December 31, 2016 were included in the study. Patients diagnosed after January 1, 1998 were included. Those treated before this date were intentionally omitted, as most of the hospitals did not start performing SLNB in patients considered at risk for regional lymphatic metastasis until 1998.[3](#cam42358-bib-0003){ref-type="ref"} All the databases complied with the relevant laws. The study was approved by the institutional review board of Hospital Universitario Reina Sofía in Córdoba (Spain) which acted as a reference committee.

2.1. Inclusion criteria and case definition {#cam42358-sec-0003}
-------------------------------------------

All patients ≥18 years old with a solitary localized melanoma, without evidence of metastasis at diagnosis with a thickness of 1 mm or less were analyzed, regardless of whether or not they had undergone SLNB. They had been included consecutively and prospectively in the relevant databases. SLNB was performed in a similar way in all centers and used any combination of vital blue dye, radioactive dye, radioactive colloid and preoperative lymphoscintigraphy for location SLN. The surgical management of primary melanoma was performed with a 1 cm wide excision, as recommended by most guidelines.

Pathologic examination of the sentinel lymph nodes at each hospital was performed using standard procedures that have previously been described.[11](#cam42358-bib-0011){ref-type="ref"} The HCUB has been applying the Minitub protocol (EORTC 1208: Minitub registration study) since 2011.

2.2. Independent variables {#cam42358-sec-0004}
--------------------------

Drawing on the literature and the available evidence, the following clinical and pathologic variables were chosen as independent variables:

Clinical characteristics: sex, age (continuous variable classified as \<40, 40‐65, and \>65 years), and anatomic location (head/neck, trunk, upper extremities, or lower extremities).

Histologic characteristics: Breslow thickness, mitotic rate, ulceration, regression, lymphovascular invasion, Clark level, and histologic subtype. For thickness, patients were reclassified according to the new AJCC staging criteria (\<0.8 mm vs ≥0.8 mm). Thickness was rounded to the nearest decimal point (0.1 mm), as recommended by the AJCC.[3](#cam42358-bib-0003){ref-type="ref"} Mitotic rate (number of mitoses/mm^2^) was evaluated using the hot spot method, which consists of identifying the area of the dermis with the highest number of mitotic figures and counting the mitoses in adjacent fields until an area of 1 mm^2^ is reached. The previously established cutoffs of 0, 1, 2, and \>2 mitoses/mm^2^ were used.[12](#cam42358-bib-0012){ref-type="ref"} Ulceration, regression, and lymphovascular invasion were evaluated as presence or absence and Clark level was divided into levels II‐III vs IV‐V.

The type of recurrence was recorded (locoregional, regional or distant recurrence).

2.3. Outcomes {#cam42358-sec-0005}
-------------

The primary outcome measures for the overall population were disease‐free interval (DFI) and melanoma‐specific survival (MSS). Survival was measured from time of primary tumor excision to time of local, regional lymphatic, or distant recurrence or death due to melanoma (respective events for DFI and MSS), or to time of last follow‐up or death due to a cause other than melanoma (whichever happened first). National death records were used by some hospitals to evaluate the vital status in patients.

2.4. Statistical analysis {#cam42358-sec-0006}
-------------------------

Difference between SLN status and variables was investigated with chi‐square test. Survival curves were built using the Kaplan‐Meier method and compared using the log rank test. Cox proportional hazards regression analysis was used for the multivariate analysis including and the assumption of proportionality was evaluated graphically using a log‐log graph. Missing values were imputed using multiple imputation, for which 10 full datasets were created. The estimates were combined using Rubin\'s rules.[13](#cam42358-bib-0013){ref-type="ref"} Before running the model, SPSS\'s missing value add‐on module was used to check whether the missing data were missing at random. The variables that have been imputed were age, sex, anatomic location, mitotic rate, ulceration histologic, subtype, lymphovascular invasion, regression and Clark level, with different levels of missingness. And variables without missing values were used to impute and recreate the scenario of values under missing at random assumption (MAR).

The dependent variable for patients who underwent SLNB was a positive result. Binomial logistic regression analysis was used to evaluate the effects of the independent variables on the likelihood of SLN positivity, using variables potentially associated with SLN status in the univariate model (*P* \< 0.2) for the multivariate model with a backward stepwise elimination and multivariate analysis of Cox proportional hazards models were performed after multiple imputation and were adjusted for all the study variables: age, sex, anatomic location, Breslow thickness, ulceration, mitotic rate, histologic subtype, Clark level, lymphovascular invasion, and regression. The variable *hospital* was not included in the binomial logistic regression model to avoid oversaturation.

Statistical significance was set at a P value of less than 0.05. All statistical analyses were performed in SSPS 20.0 (Illinois, Inc; USA).

3. RESULTS {#cam42358-sec-0007}
==========

We analyzed data for 4249 patients with thin melanoma (≤1 mm); of this entire cohort, 1897 patients were men (44.6%) and 2352 were women (55.4%). The median age was 57.8 years (interquartile range, 40‐66 years). The most common age for diagnosis was 41‐65 years (48.1%) and the most common anatomic location was the trunk (42.4%). Absence of mitosis was the most common finding (67%) and superficial spreading melanoma was the most common histologic subtype. A tumor thickness of \<0.8 mm was reported for 71% of patients. The characteristics of the population are summarized in Table [1](#cam42358-tbl-0001){ref-type="table"}.

###### 

Characteristics of 4249 patients with thin melanoma according to the 8th edition of the American Joint Committee on Cancer Staging Manual

  Characteristic                                    No.       \%
  ------------------------------------------------- --------- ------
  Sex                                                         
  Male                                              1897      44.6
  Female                                            2352      55.4
  Age of diagnosis                                            
  Median                                            57.8      
  p75‐p25                                           40‐66     
  ≤40 y old                                         1120      26.5
  41‐65 y old                                       2034      48.1
  \>65 y old                                        1071      25.3
  Anatomic location (missing = 133; 3.1%)                     
  Head and neck                                     494       12
  Trunk                                             1746      42.4
  Upper extremities                                 1261      30.6
  Lower extremities                                 615       14.9
  Breslow thickness                                           
  Median                                            0.6       
  p75‐p25                                           0.4‐0.8   
  \<0.8                                             3018      71
  0.8‐1.0                                           1231      29
  Ulceration (missing = 495; 11.6%)                           
  Absent                                            3613      96.2
  Present                                           141       3.8
  Mitotic rate (missing = 1752; 41.2%)                        
  0 mitoses/mm^2^                                   1674      67
  1 mitosis/mm^2^                                   514       20.6
  2 mitoses/mm^2^                                   176       7
  \>2 mitoses/mm^2^                                 133       5.3
  Histologic subtypes (missing = 64; 1.5%)                    
  LMM                                               346       8.3
  SSM                                               3487      83.3
  NM                                                89        2.1
  ALM                                               94        2.2
  Other                                             169       4
  Clark level (missing = 973; 22.9%)                          
  II‐III                                            2838      86.6
  IV‐V                                              438       13.4
  Lymphovascular invasion (missing = 1887; 44.4%)             
  Absent                                            2287      99.3
  Present                                           15        0.4
  Regression (missing = 848; 20%)                             
  Absent                                            2175      64
  Present                                           1226      36
  Hospital                                                    
  1                                                 130       3.1
  2                                                 698       16.4
  3                                                 984       23.2
  4                                                 1210      28.5
  5                                                 505       11.9
  6                                                 80        1.9
  7                                                 284       6.7
  8                                                 247       5.8
  9                                                 109       2.6

Hospital: 1. Hospital Universitario de Salamanca (Salamanca, Spain); 2. Instituto Valenciano de Oncología (Valencia, Spain); 3. Hospital Clìnic (Barcelona, Spain); 4. Hospital de Turin (Turin, Italy); 5. Hospital German Trials i Pujol (Badalona, Spain); 6. Hospital de Coimbra (Coimbra, Portugal); 7. Hospital Universitario A Coruña (A Coruña, Spain); 8. Hospital Virgen Macarena (Seville, Spain); 9. Hospital La Fe (Valencia, Spain).

Abbreviations: ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma.

John Wiley & Sons, Ltd

After a median follow‐up of 68 months, 158 patients (3.7%) experienced disease recurrence (locoregional 22.9%, regional 34.6%, and distant 42.5%) and 77 (1.8%) died of melanoma (uncensored in the survival analysis).

For the overall population (*n* = 4249), sex, Breslow thickness, ulceration, Clark level, and histologic subtype were all significantly associated with DFI and MMS (Table [2](#cam42358-tbl-0002){ref-type="table"}). On analyzing SNLB patients only (*n* = 1083), SLN status was the most important prognostic factor for both DFI (hazard ratio 7.4; 95% CI, 4.1‐13.5) (*P* \< 0.001) and MSS (hazard ratio, 12.8; 95% CI 5.4‐30.2) (*P* \< 0.001). Additional independent predictors of DFI and MSS were sex, age, Clark level, and ulceration (Table [2](#cam42358-tbl-0002){ref-type="table"}).

###### 

Multivariate Cox regression model for disease‐free interval and melanoma‐specific survival in the entire cohort and in patients who underwent sentinel lymph node biopsy

  Variable                                Hazard ratio   95% CI     *P* value
  --------------------------------------- -------------- ---------- -----------
  Entire cohort (*n* = 4249)                                        
  Disease‐free interval                                             
  Sex (female vs male)                    0.7            0.5‐0.8    0.006
  Ulceration (presence vs absence)        2.4            1.3‐4.3    0.006
  Others vs LMM                           0.3            0.2‐0.9    0.031
  ≥0.8 mm vs \<0.8 mm Breslow thickness   1.6            1.1‐3      0.01
  Clark level (IV‐V vs II‐III)            3.1            2‐4.8      \<0.001
  Melanoma‐specific survival                                        
  Sex (female vs male)                    0.4            0.2‐0.7    \<0.001
  Ulceration (presence vs absence)        2.9            1.4‐6.1    0.005
  ALM vs LMM                              15.1           2.3‐98.6   0.004
  ≥0.8 mm vs \<0.8 mm Breslow             1.9            1.1‐3.2    0.021
  Clark level (IV‐V vs II‐III)            3              1.6‐5.7    0.001
  Patients underwent SLNB (*n* = 1090)                              
  Disease‐free interval                                             
  Sex (female vs male)                    0.5            0.3‐0.9    0.027
  Age \>5 vs \<40                         2.5            1.1‐5.7    0.028
  Ulceration (presence vs absence)        3              1.5‐5.9    0.002
  Clark level (IV‐V vs II‐III)            2.8            1.6‐4.9    \<0.001
  SLNB (positive vs negative)             7.4            4.1‐13.5   \<0.001
  Melanoma‐specific survival                                        
  Sex (female vs male)                    0.3            0.1‐0.6    0.004
  Age \>65 vs \<40                        3.5            1‐12.1     0.044
  Ulceration (presence vs absence)        4.3            1.7‐10.4   0.001
  Clark level (IV‐V vs II‐III)            2.6            1.1‐6.1    0.022
  SLNB (positive vs negative)             12.8           5.4‐30.2   \<0.001

Abbreviations: ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; SLNB: Sentinel lymph node biopsy.

John Wiley & Sons, Ltd

The cumulative estimated survival rates for T1a melanoma patients at 5, 10, and 15 years, respectively, were 97.6%, 96.1%, 93.2% for DFI, and 99.5%, 98.5%, and 97.2% for MSS (Figure [1](#cam42358-fig-0001){ref-type="fig"}A and [1](#cam42358-fig-0001){ref-type="fig"}B) (*P* \< 0.001). The corresponding rates for patients with T1b melanoma were 93.3%, 88.5%, and 80.8% for DFI and 96.3%, 94.8%, and 88.6% for MSS (Figure [1](#cam42358-fig-0001){ref-type="fig"}A and [1](#cam42358-fig-0001){ref-type="fig"}B) (*P* \< 0.001).

![Kaplan‐Meier disease‐specific survival curves for patients with thin melanoma according to the staging criteria of the 8th edition of the American Joint Committee on Cancer Staging Manual, T1a vs T1b](CAM4-8-4235-g001){#cam42358-fig-0001}

The characteristics of the patients who underwent SLNB are summarized by SLN status in Table [1](#cam42358-tbl-0001){ref-type="table"}. Of the 1083 patients with thin melanoma who underwent SLNB, 73 (6.7%) had a positive result. The median of positive SLNB patients was higher than negative SLNB (0.9 vs 0.8 mm). Only Breslow thickness (odd ratio \[OR\] 1.7 \[95% CI, 1‐2.92\]; *P* = 0.05) and mitotic rate (\>2 mitoses/mm^2^) (OR, 3.4 \[95% CI, 1.5‐7.7\]; *P* = 0.003) were associated with a positive status in the univariate analysis. In the multivariate analysis, only mitotic rate retained its prognostic significance (OR, 2.9 \[95% CI, 1.22‐7\]; *P* = 0.01) (Table [3](#cam42358-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate analysis of predictive factors for positive sentinel lymph node biopsy in 1090 patients with thin melanoma

  Independent variable      Univariate analysis   Multivariate analysis          
  ------------------------- --------------------- ----------------------- ------ ----------------
  Sex                                                                            
  Female                                          1                              ---
  Male                      0.21                  0.74 (0.52‐1.21)        ---    ---
  Age, y                                                                         
  \<40                                            1                              
  40‐65                     0.25                  0.72 (0.41‐1.26)        ---    ---
  \>65                      0.78                  0.91 (0.47‐1.75)        ---    ---
  Anatomic location                                                              
  Head/neck                                       1                              ---
  Trunk                     0.89                  1.06 (0.43‐2.59)        ---    ---
  Upper extremities         0.57                  0.75 (0.29‐1.96)        ---    ---
  Lower extremities         0.73                  0.84 (0.30‐2.32)        ---    ---
  Breslow thickness                                                              
  \<0.8 mm                                        1                              
  0.8‐1 mm                  0.05                  1.7 (1‐2.92)            ---    ---
  Ulceration                                                                     
  Present                   0.6                   1.22 (0.61‐1.63)        ---    ---
  Absent                                          1                              
  Mitosis rate                                                                   
  0 mitoses/mm^2^                                 1                              1
  1 mitosis/mm^2^           0.5                   1.3 (0.6‐2.9)           0.5    1.3 (0.6‐2.9)
  2 mitoses/mm^2^           0.06                  2.23 (0.97‐5.14)        0.08   2.1 (0.9‐4.95)
  \>2 mitoses/mm^2^         0.003                 3.42 (1.52‐7.73)        0.01   2.9 (1.22‐7)
  Regression                                                                     
  Present                                         1                              ---
  Absent                    0.39                  1.27 (0.73‐2.19)        ---    ---
  Clark level                                                                    
  II‐III                                          1                              ---
  IV‐V                      0.18                  1.41 (0.84‐2.37)        ---    ---
  Histologic subtype                                                             
  LMM                                             1                              ---
  SSM                       0.61                  1.44 (0.31‐6.13)        ---    ---
  NM                        0.34                  2.22 (0.42‐11.7)        ---    ---
  Others                    0.47                  0.48 (0.06‐3.46)        ---    ---
  Lymphovascular invasion                                                        
  Present                   0.71                  1.44 (0.19‐10.9)        ---    ---
  Absent                                          1                              

John Wiley & Sons, Ltd

The frequency of positive SLNB results for each combination of mitotic rate and clinical stage (T1a vs T1b) was evaluated according to the different recommendations and criteria described in the NCCN and ASCO‐SSO guidelines (Table [4](#cam42358-tbl-0004){ref-type="table"}). Patients with T1a melanoma had an SLN positivity rate of 3.4% and this rose to 20% in those with ≥2 mitosis/mm^2^. The overall SLN positivity rate in patients with T1b melanoma was 8%, but this fell to 3.6% in the subgroup of patients with 0 mitosis/mm^2^. Based on the NCCN recommendations for stage T1a thin melanoma with ≥2 mitosis/mm^2^, the SLN positivity rate was 7.8%. None of the 17 patients in the younger age group (\<40 years) had a positive SLNB. We were unable to evaluate the frequency of positive SLNB results in patients with lymphovascular invasion, as there were just three cases.

###### 

Association between SLN status and different tumor staging criteria for thin melanoma within the framework of current guideline recommendations for SLN biopsy

  Scenario                                                             All patients   SLN positivity *n* (%)   NCCN guidelines   ASCO‐SSO guideline   Present study
  -------------------------------------------------------------------- -------------- ------------------------ ----------------- -------------------- --------------------------------------------
  T1a (NCCN)                                                                                                                                          
  ≥2 mitoses/mm^2^                                                     51             4 (7.8)                  DC                NR                   DC
  Lymphovascular invasion                                              3              0 (0)                    DC                NR                   [\*\*](#cam42358-note-0007){ref-type="fn"}
  ≥2 mitoses/mm^2^+ young age[a](#cam42358-note-0006){ref-type="fn"}   17             0 (0)                    DC                NR                   NR
  T1a (present study)                                                                                                                                 
  All                                                                  358            12 (3.4)                 NR                NR                   NR
  0 mitoses/mm^2^                                                      84             1 (1.2)                  NR                NR                   NR
  1 mitosis/mm^2^                                                      121            3 (2.5)                  NR                NR                   NR
  2 mitoses/mm^2^                                                      36             1 (2.8)                  DC                NR                   NR
  \>2 mitoses/mm^2^                                                    15             3 (20)                   DC                NR                   DC
  T1b (present study)                                                                                                                                 
  All                                                                  713            57 (8)                   DC                DC                   DC
  0 mitoses/mm^2^                                                      168            6 (3.6)                  DC                DC                   NR
  1 mitosis/mm^2^                                                      164            11 (6.7)                 DC                DC                   DC
  2 mitoses/mm^2^                                                      80             11 (13.8)                DC                DC                   DC
  \>2 mitoses/mm^2^                                                    68             9 (13.2)                 DC                DC                   DC

Abbreviations: DC, discuss and consider; NR: not recommended; SLN, sentinel lymph node.

\<45 years old.

Insufficient number.

John Wiley & Sons, Ltd

Over a median follow‐up of 64 months for patients in the SLNB subgroup, 58 patients experienced disease recurrence (locoregional 26.3%, regional 19.3%, and distant 54.5%) and 30 died of melanoma. DFI at 5 and 10 years was, respectively, 96.5% and 94.1% for SLN‐negative patients and 72.2% and 64.5% for SLN‐positive patients (*P* \< 0.001)(Figure [2](#cam42358-fig-0002){ref-type="fig"}A). Five‐and 10‐year MSS, by contrast, was 98.7% and 97.6% for SLN‐negative patients and 83.8% and 74.3% for SLN‐positive patients (*P* \< 0.001) (Figure [2](#cam42358-fig-0002){ref-type="fig"}B).

![Kaplan‐Meier survival curves for patients with thin melanoma according to sentinel lymph node status: (A) Disease‐free interval; (B) Melanoma‐specific survival](CAM4-8-4235-g002){#cam42358-fig-0002}

The number of false negative patients was nine. The false negative rate was 10.8%. This was calculated by dividing the number of false negatives by the sum of false negatives plus true positives following van Akkooi\'s method.[14](#cam42358-bib-0014){ref-type="ref"}

4. DISCUSSION {#cam42358-sec-0008}
=============

This study shows that SLN status is the most important prognostic factor in thin melanoma. Coinciding with the revised AJCC staging system,[3](#cam42358-bib-0003){ref-type="ref"} the most important factors for MSS, not counting SLN status, were Breslow thickness and ulceration, followed by sex, Clark level, and acral lentiginous melanoma.

It is noteworthy that 5‐year MSS of positive SLNB patient is worse in our study with respect to other similar studies~.~ [15](#cam42358-bib-0015){ref-type="ref"}, [16](#cam42358-bib-0016){ref-type="ref"} It is probably due to a difference in the selection of patients who underwent the SLNB.

Female sex confers a survival benefit in thin melanoma. Although this benefit is widely recognized,[17](#cam42358-bib-0017){ref-type="ref"}, [18](#cam42358-bib-0018){ref-type="ref"} no logical explanation has yet been found.

The findings of our study support a prognostic role for Clark level in thin melanoma. Clark level, defined by Wallace Clark,[19](#cam42358-bib-0019){ref-type="ref"} was considered a prognostic factor in thin melanoma in earlier editions of the AJCC Cancer Staging Manual, but it was replaced by mitogenicity in the 6th edition.[20](#cam42358-bib-0020){ref-type="ref"} Clark level is less reproducible than tumor thickness for pathologists as its interpretation is limited by differences between the papillary and reticular dermis in patients with solar elastosis or in certain areas, such as the scalp, acral sites, and mucosal membranes.

Acral lentiginous melanoma is a subtype of melanoma defined by the World Health Organization.[21](#cam42358-bib-0021){ref-type="ref"} The Clark classification of melanomas, which is based on different epidemiological and genetic features, is not free of criticism due to the overlapping of the histopathologic criteria on which it is based.[22](#cam42358-bib-0022){ref-type="ref"}

Several reasons for the worse prognosis associated with acral lentiginous melanoma have been postulated, including differences in mutations and amplifications, such as a lower incidence of *BRAF*/*NRAS* mutations,[20](#cam42358-bib-0020){ref-type="ref"} a higher incidence of *KIT* mutations or amplifications,[23](#cam42358-bib-0023){ref-type="ref"} and amplification of the *TERT* gene[24](#cam42358-bib-0024){ref-type="ref"} in melanomas classified using the Clark system.

Although SLN status has been identified as the most important prognostic factor in thin melanoma,[16](#cam42358-bib-0016){ref-type="ref"}, [25](#cam42358-bib-0025){ref-type="ref"} there is no consensus on which patients should be offered SLNB. The updated ASCO‐SSO guideline does not recommend SLNB for T1a melanomas.[9](#cam42358-bib-0009){ref-type="ref"} Version 1.2018 of the NCCN melanoma guidelines, however, which incorporate the AJCC\'s latest modifications to the staging criteria for thin melanoma,[8](#cam42358-bib-0008){ref-type="ref"} recommend the procedure if the risk of a positive SLN is more than 5%. In the specific case of thin melanoma, it recommends considering SLNB in patients with "T1a lesions \<0.8 mm with other adverse features (eg. very high mitotic index ≥2/mm^2^ \[particularly in the setting of young age\], lymphovascular invasion, or a combination of these factors)." This recommendation, however, is not supported by clinical studies.

Our findings support the indication for SLNB in patients with T1a melanoma and a high mitotic rate (\>2/mm^2^). We found no significant associations with patient age. Lymphovascular invasion was not included in the regression model as it was only identified in 15 patients and none of them had SLN metastasis.

Another noteworthy finding in our study was the low rate of SLN positivity (just 3.6%) in patients with T1b melanoma without mitosis. In a recent study of 203 cases of thin melanoma, a similarly low rate was reported for patients with T1b melanoma without mitoses or with a low mitotic rate.[12](#cam42358-bib-0012){ref-type="ref"} Bartlett et al,[26](#cam42358-bib-0026){ref-type="ref"} in a study of 781 patients with thin melanoma who underwent SLNB, also found absence of mitotic activity to be associated with a low probability of SLN metastasis, even in patients with thin melanomas \>0.75 mm. Although the ASCO‐SSO and NCCN clinical practice guidelines recommend SLNB for patients with T1b melanoma, perhaps the option of not performing the procedure should be contemplated in patients without mitoses.

Previous studies have not found significant associations between mitotic rate and SLN status in thin melanoma,[27](#cam42358-bib-0027){ref-type="ref"}, [28](#cam42358-bib-0028){ref-type="ref"}, [29](#cam42358-bib-0029){ref-type="ref"} but this is probably because they analyzed small samples or used different cutoff points.[16](#cam42358-bib-0016){ref-type="ref"} Han et al[15](#cam42358-bib-0015){ref-type="ref"} is one of the most numerous studies, did not find any factor related to at least 5% of possibility to have a positive SLN in melanomas \<0.75 mm in dept. In a recent study of thin melanomas from the US National Cancer Database, Wheless et al[30](#cam42358-bib-0030){ref-type="ref"} observed a positive linear relationship between mitotic rate and increased odds of SLN involvement. A greater likelihood of SLN metastasis in the presence of dermal mitoses in thin melanoma has also been reported elsewhere.[31](#cam42358-bib-0031){ref-type="ref"}, [32](#cam42358-bib-0032){ref-type="ref"} Unlike us, however, the authors did not quantify the number of mitoses.

Our study has some limitations, including its retrospective design and the fact that data were missing for some variables. Information on mitotic rate, for example, was missing for 41.2% of patients. On analyzing the differences between patients with and without data on mitotic rate, we found no differences for Breslow thickness or ulceration (data not shown). Another possible limitation of our study is that it was performed in southern Europe, where there is a low incidence of melanoma compared with other areas of the continent. The SLN positivity rate for patients with thin melanoma in our study was 6.7%, but on counting the false negatives, it was 7.5%, which is higher than in other series.[26](#cam42358-bib-0026){ref-type="ref"} It can be assumed, however, that this higher rate did not affect the aim of the study. Our study also has important strengths, such as its multicenter design and the large number of patients analyzed. Finally, the adequacy of the follow‐up period is assured by the similarities observed between the survival rates in our study and those reported by the AJCC for thin melanoma.

5. CONCLUSIONS {#cam42358-sec-0009}
==============

SLN involvement is the most important prognostic factor among patients undergoing SLNB in thin melanoma. High mitotic rate is associated with SLN metastasis but probably has no impact on survival in patients with thin melanoma. SLNB should be recommended in patients with T1a melanoma and a high mitotic rate, as even though this combination is uncommon, it is associated with a high risk of SLN metastasis. Sex, acral lentiginous melanoma, and Clark level were also independently associated with survival in our cohort and should be taken into account when devising new staging systems. More studies, however, are needed to validate our findings.
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